Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients

Abstract

AIM:To investigate the clinical relevance and prognosis regarding survival according to the changes of the tumor-node-metastasis (TNM) in gastric cancer patients. METHODS:We retrospectively studied 347 consecutive subjects who underwent surgery for gastric adenocarcinoma at the Division of General Surgery, Hospital of Busto Arsizio, Busto Arsizio, Italy between June 1998 and December 2009. Patients who underwent surgery without curative intent, patients with tumors of the gastric stump and patients with tumors involving the esophagus were excluded for survival analysis. Patients were staged according to the 6 th and 7 th edition TNM criteria; 5-year overall survival rates were investigated, and the event was defined as death from any cause. RESULTS:After exclusion, our study population included 241 resected patients with curative intent for gastric adenocarcinoma. The 5-year overall survival (5-year OS) rate of all the patients was 52.8%. The diagnosed stage differed in 32% of 241 patients based on the TNM edition used for the diagnosis. The patients in stage Ⅱ according to the 6 th edition who were reclassified as stage Ⅲ had significantly worse prognosis than patients classified as stage Ⅱ (5-year OS, 39% vs 71%). According to the 6 th edition, 135 patients were classifed as T2, and 75% of these patients migrated to T3 and exhibited a significantly worse prognosis than those who remained T2, regardless of lymph node involvement (37% vs 71%). The new N1 patients exhibited a better prognosis than the previous N1 patients (67% vs 43%). CONCLUSION: 7th TNM allows new T2 and N1 patients to be selected with better prognosis, which leads to different staging. New stratification is important in multimodal therapy.

miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression

“…All the samples were pathologically examined and stored in liquid nitrogen for miRNA analysis. The stage and histological type of the tumor were defined according to the 7th edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system [14]. Ethical approval of the study was granted by the Clinical Research Ethics Committee, Nanjing Medical University.…”

Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy

“…Thus, it is important to select patients who can expect a relatively good prognosis with aggressive treatment. In the 6th Edition of the Union for International Cancer Control (UICC) TNM classification, stage IV included distant metastasis-negative (M0) cases and distant metastasis-positive (M1) cases [10]. However, in some stage IV patients, patients with M0 showed a significantly better survival rate than those with M1, and patients with M0 were good candidates for aggressive treatment [11][12][13].…”

Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression

“…The protocol of the present study was approved by the Sun-Yat Sen University Institutional Review Board, and included keeping all tissues frozen, and collecting 42 non-cancerous tissue samples that were located >5 cm away from the primary tumor edge site. The stage and histological type of the tumor were defined according to the 7th edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system (24). The relevant clinicopathological data collected included age, gender, pathological tumor-node-metastasis (p-TNM) stage, lymph node metastasis (LNM), differentiation, depth of invasion and follow-up to overall survival (OS).…”